secwatch.observer — SEC 8-K summary
======================================

Issuer:     CYTOKINETICS INC (CYTK)
CIK:        0001061983
Form:       8-K
Filed at:   2026-08-06T20:11:43+00:00
Accession:  0001193125-26-338021
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cytokinetics Q2 net loss $198.8M; MYQORZO revenue $25M; ACACIA-HCM positive
---------------------------------------------------------------------------

- Total revenues $28.6M (Q2 2025: $66.8M) including $25.3M MYQORZO net product revenue; no license/milestone revenue in Q2 2026.
- Net loss $198.8M ($1.50/share) vs $134.4M ($1.12) in Q2 2025; R&D $97.8M, SG&A $104.4M.
- Cash, equivalents and investments $1.7B (up from $1.1B at Mar 31, 2026) after $760.1M net from public offering of 11.3M shares at $71.
- ACACIA-HCM (nHCM) met dual primary endpoints; supplemental NDA for aficamten in nHCM expected Q4 2026.
- FY 2026 GAAP combined R&D+SG&A guidance raised to $860M-$890M from $830M-$870M; over 700 prescribers, ~1,500 patients dispensed MYQORZO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1061983/000119312526338021/0001193125-26-338021-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1061983/000119312526338021/cytk-20260806.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-338021

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer